Dr. David Fajgenbaum, MD, MBA, MSc, FCPP, is the Co-founder of the TRND Network, the Castleman Disease Collaborative Network (CDCN), Founding Director of the Center for Cytokine Storm Treatment & Laboratory (CSTL), Associate Director of Patient Impact for the Orphan Disease Center, and Assistant Professor of Medicine in Translational Medicine & Human Genetics at the University of Pennsylvania, and national bestselling author of Chasing My Cure: A Doctor’s Race to Turn Hope Into Action. He currently leads over 20 translational research studies.
One of the youngest individuals ever appointed to the faculty at Penn Medicine and the top 1 percent youngest awardees of a leading NIH grant, Dr. Fajgenbaum has published scientific papers in high-impact journals such as the New England Journal of Medicine, Journal of Clinical Investigation, and Lancet, been recognized with awards such as the 2016 Atlas Award along with then Vice President Joe Biden, and profiled in a cover story by The New York Times as well as by Good Morning America, CNN, Science, Forbes 30 Under 30, and the Today Show, among others. He also serves on the Board of Directors for the Reagan-Udall Foundation for the FDA, co-Chair of the Advisory Board for the CURE Drug Repurposing Collaboratory, and co-Chair of the Scientific Advisory Board for the CDCN.
Before co-founding the TRND Network, Dr. Fajgenbaum co-founded and continues to lead the CDCN Network. Dr. Fajgenbaum earned a BS from Georgetown University magna cum laude with honors and distinction, MSc from the University of Oxford as the 2007 Allbritton Scholar, MD from the University of Pennsylvania Medical School as a 21st Century Gamble Scholar, and MBA from The Wharton School, where he was awarded the Mandel Fellowship, Kissick Scholarship, Joseph Wharton Award, Eilers Health Care Management Award, and Commencement Speaker.